OSE Immunotherapeutics: New Governance and Strategic Objectives

OSE Immunotherapeutics, a French biotechnology company, is proposing changes to its governance ahead of its annual general meeting. This initiative aims to rebalance shareholder representation on the board of directors by integrating independent directors and representatives of concerted shareholders. This change aims to establish a more agile and strategically aligned board to support the development of its two therapeutic platforms, Tedopi® and Lusvertikimab.

The company plans to strengthen its strategy by maximizing the potential of oncology and inflammation treatments, while pursuing key financing strategies and partnerships. Tedopi®'s Phase 3 trial for lung cancer is progressing, and Lusvertikimab will enter a targeted Phase 2b trial. The meeting will be held on September 30, 2025, with shareholders able to vote online.